Home›Stock Screener›Aarti Pharma Labs

Aarti Pharma Labs Share Price Today | Stock Price & Aarti Pharma Labs Share Screener

AARTIPHARM Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1013.40
▼ -2.50 (-0.25%)
2026-11-18 00:00:00
Live Share Price BSE
₹1011.55
▼ -4.85 (-0.48%)
2026-11-18 00:00:00

As of November 18, 2026, the live Aarti Pharma Labs share price (NSE: AARTIPHARM) is ₹1,013.40 on NSE and ₹1,011.55 on BSE, down 0.25% from the previous close, with shares trading between ₹992.45 and ₹1,028.95 in today's trading session, and a 52-week range of ₹591.95–₹1,015.90. Track Aarti Pharma Labs market worth to gauge the company's total market size. Use the Aarti Pharma Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Aarti Pharma Labs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹618 and net income of ₹72, with EBITDA of ₹141, an operating margin of 22.0% and a profit margin of 11.7%.

Aarti Pharma Labs Market Cap ₹9,212.16 Cr.
AARTIPHARM P/E Ratio (TTM) 34.80
Aarti Pharma Labs P/B Ratio 3.97
EPS (TTM) ₹19.27
Dividend Yield 0.35%
Debt to Equity 0.28
AARTIPHARM 52 Week High ₹1015.90
Aarti Pharma Labs 52 Week Low ₹591.95
Operating Margin 22.00%
Profit Margin 11.65%
AARTIPHARM Revenue (TTM) ₹618.00
EBITDA ₹141.00
Net Income ₹72.00
Total Assets ₹3,482.00
Total Equity ₹2,125.00

Aarti Pharma Labs Share Price Chart

Track the current stock price of Aarti Pharma Labs with an interactive chart. Analyse AARTIPHARM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Aarti Pharma Labs stock quote in one place.

The quote of ₹1,013.40 sits between the 52-week low of ₹591.95 and the 52-week high of ₹1,015.90, and the latest session moved -0.25% from the previous close.

Aarti Pharma Labs Company Profile - Fundamental Screener

Screen Aarti Pharma Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AARTIPHARM shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE0LRU01027.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE0LRU01027

Aarti Pharma Labs Balance Sheet Screener

Screen AARTIPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹3,482, up from ₹2,906 in 2025.

Latest statistics put total assets at ₹3,482 and shareholder funds at ₹2,125, with a leverage ratio of 0.28.

Item 2026 2025 2024 2023 2022 2021

Assets

Total Assets 3,482 2,906 2,582 2,244 2,040 0
Current Assets 0 0 0 0 0 0
Fixed Assets 1,438 1,137 1,033 926 782 0

Liabilities

Total Liabilities 0 0 0 0 0 0
Current Liabilities 420 259 131 85 73 0
Non-Current Liabilities 0 0 0 0 0 0

Shareholders' Equity

Total Equity 2,125 1,990 1,757 1,559 1,387 0
Share Capital 45 45 45 45 0 0
Reserves & Surplus 2,079 1,945 1,712 1,513 1,341 0

Aarti Pharma Labs Income Statement Screener - Profit & Revenue Analysis

Screen Aarti Pharma Labs income statement and profit fundamentals. Analyze AARTIPHARM quarterly results. Aarti Pharma Labs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹618 and net profit was ₹72, equal to earnings per unit of ₹7.88, at an operating margin of 22%.

In that period expenses were ₹477, interest cost ₹15 and tax ₹24. The next period listed, 2026-Jun, shows revenue of ₹544 and net profit of ₹76.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Mar 2024-Jun 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 618 544 596 437 418 388 562 543 463 508 558 486 459 441 450
Expenses 477 400 470 333 344 293 418 409 364 388 459 405 374 352 353

Operating Costs and Margins

EBITDA 141 144 127 104 74 95 144 134 98 120 99 81 85 89 97
Operating Profit % 22.00% 25.00% 19.00% 23.00% 18.00% 24.00% 26.00% 24.00% 20.00% 23.00% 17.00% 16.00% 19.00% 20.00% 21.00%
Depreciation 31 30 28 29 25 23 23 23 21 19 20 16 17 18 19
Interest 15 13 17 13 11 7 7 10 6 5 5 6 4 4 5

Profit and Earnings

Profit Before Tax 95 101 82 63 39 65 115 101 72 96 74 59 64 67 74
Tax 24 25 21 15 11 16 26 27 17 31 18 16 17 15 21
Net Profit 72 76 61 48 28 50 88 74 55 65 56 43 47 52 53
EPS 7.88 8.40 6.74 5.29 3.08 5.46 9.75 8.16 6.03 7.20 6.12 4.73 5.20 5.72 5.82

Aarti Pharma Labs Cash Flow Screener - Liquidity Fundamentals

Screen AARTIPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹262, and net cash flow was an inflow of ₹2.

Over the same period, investing activities used ₹431 and financing activities provided ₹171.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March

Cash from Operations and Investing

Operating Activities 262 330 216 250 -44 0
Investing Activities -431 -413 -215 -158 -139 0

Financing and Net Cash

Financing Activities 171 65 10 -164 260 0
Net Cash Flow 2 -17 12 -71 78 0

Aarti Pharma Labs Shareholding Pattern Screener

See Aarti Pharma Labs shareholding pattern with promoter, FII, and DII holdings. Check Aarti Pharma Labs promoter holding and ownership changes for AARTIPHARM on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 39.66%, foreign institutions 8.15%, domestic institutions 8.40% and the public 35.65%, spread across 174,329 shareholders.

The shareholder count was 174,329 in 2026-Sept, compared with 176,506 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 39.66% 42.86% 43.08% 43.10% 42.88% 43.72% 44.29% 44.66%

Institutional Investors

FII Holding 8.15% 8.17% 8.39% 7.68% 8.02% 7.35% 7.36% 8.64%
DII Holding 8.40% 7.22% 7.41% 7.66% 6.96% 7.80% 7.53% 10.36%

Government, Public and Others

Govt Holding 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
Public Holding 35.65% 34.39% 34.29% 34.85% 35.39% 34.43% 34.10% 30.39%
Other Holding 8.13% 7.35% 6.82% 6.70% 6.74% 6.69% 6.71% 5.94%
Shareholder Count 174,329 176,506 179,373 184,489 190,655 187,039 196,314 185,111

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Aarti Pharma Labs. Aarti Pharma Labs dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹3.50 per unit for 2026-March, a yield of 0.35%, compared with ₹5.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹3.50, ₹5.00 and ₹3.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹3.50 0.35%
2025-March ₹5.00 0.84%
2024-March ₹3.00 0.40%
2023-March ₹2.00 0.46%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Aarti Pharma Labs Stock Index Membership - Nifty & Sensex

See which indices include Aarti Pharma Labs stock. Check AARTIPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 5 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT

Aarti Pharma Labs Market Events Screener - Corporate Actions

Get Aarti Pharma Labs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Aarti Pharma Labs stock events that may affect AARTIPHARM share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 28, 2026, with a record date of October 28, 2026.

It is followed by Annual General Meeting dated September 22, 2026 and Dividend dated September 15, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-28 2026-10-28 Quarterly Result Announcement NA 0.78%
2026-09-22 2026-09-22 Annual General Meeting NA -0.67%
2026-09-15 2026-09-15 Dividend ₹ 2.00 /share 16.00%
2026-08-07 2026-08-07 Quarterly Result Announcement NA 0.58%
2026-05-25 2026-05-25 Quarterly Result Announcement NA -6.82%
2026-02-16 2026-02-16 Dividend ₹ 1.50 /share -8.86%
2026-02-09 2026-02-09 Quarterly Result Announcement NA 1.87%
2025-11-09 2025-11-09 Quarterly Result Announcement NA 3.80%
2025-09-22 2025-09-22 Annual General Meeting NA 10.17%
2025-09-15 2025-09-15 Dividend ₹ 2.50 /share 21.02%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -5.82%
2025-05-10 2025-05-10 Quarterly Result Announcement NA 1.53%
2025-02-14 2025-02-14 Dividend ₹ 2.50 /share 18.21%
2025-02-05 2025-02-05 Quarterly Result Announcement NA 4.31%
2024-10-28 2024-10-28 Quarterly Result Announcement NA -1.13%

Aarti Pharma Labs Competitors Screener - Peer Stocks Comparison

Screen AARTIPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Aarti Pharma Labs Company Announcements - News & Reports Screener

Screen AARTIPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 17, 2026.

The next most recent announcements are dated November 4, 2026 and October 30, 2026.

Date Update Actions
2026-11-17 Announcement under Regulation 30 (LODR)-Demise -
2026-11-04 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-10-30 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-29 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-10-29 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-10-28 Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026 - Uploading A Clear Version -
2026-10-28 Announcement under Regulation 30 (LODR)-Change in Management -
2026-10-28 Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) -
2026-10-28 Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026 -
2026-10-28 Board Meeting Outcome for Outcome Of Board Meeting Held On October 28 2026 -
2026-10-28 Intimation Of Revamp Of The Companys Website -
2026-10-28 Intimation Of Grant Of Options Under APL Performance Stock Option Plan- 2023 (PSOP 2023) -
2026-10-22 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-09 Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30 2026 -
2026-10-09 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-30 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-09-30 Intimation Under Regulation 30 Of SEBI Listing Regulations -
2026-09-28 Closure of Trading Window -
2026-09-23 Updates On Change In Directorate -
2026-09-23 Shareholder Meeting / Postal Ballot-Scrutinizers Report -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,013.40, within a 52-week range of ₹591.95 to ₹1,015.90. The P/E ratio is 34.80 and the P/B ratio is 3.97, with earnings per unit of ₹19.27. Market capitalisation stands at ₹9,212.16 Cr and the dividend yield is 0.35%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 6 balance sheet periods, 15 income statement periods, 6 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.